RxDoctor Payments DataLook up a doctor →

Ahmed Abdelgaber, MD

Family Medicine · Huntington, WVNPI 1194742916

Payments from drug & device makers

$14,024in general payments, 2019–2025

Across 1,007 payments — averaging $13.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • AbbVie$1K
  • Novartis$1K
  • Novo Nordisk$1K
  • Amgen$739
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$14,007100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,024 in reported general payments places this provider in the 95th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$468,155
Medicare patients
637
Services billed
6,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$196,949
OzempicSemaglutide111$169,273
JardianceEmpagliflozin120$139,280
Enbrel SureclickEtanercept13$95,388
XareltoRivaroxaban93$94,948
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$53,085
LinzessLinaclotide66$48,476
MounjaroTirzepatide36$45,964
Tresiba Flextouch U-100Insulin Degludec31$45,786
EntrestoSacubitril/Valsartan38$42,607
FarxigaDapagliflozin Propanediol44$42,296
JanuviaSitagliptin Phosphate32$38,068
Victoza 3-PakLiraglutide14$20,034
Breo ElliptaFluticasone/Vilanterol31$19,039
InvokanaCanagliflozin11$18,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$204$196,949233 claims
Novo NordiskOzempic, Rybelsus$1,079$182,612122 claims
Boehringer IngelheimJardiance, Tradjenta$384$152,452137 claims
Johnson & JohnsonXarelto, Invokana$588$113,924104 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Shingrix$1,396$85,995142 claims
AstraZenecaFarxiga, Symbicort$1,901$54,96669 claims
AbbVieLinzess$1,373$48,47666 claims
Lilly USA, LLCMounjaro$691$45,96436 claims
NovartisEntresto$1,319$42,60738 claims
MerckJanuvia$41$38,06832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →